RxDoctor Payments Data

Matthew McLaughlin, DO

Critical Care Medicine · Middletown, NYNPI 1548569965

Payments from drug & device makers

$1,535in general payments, 2019–2025

Across 86 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$273
  • GSK$242
  • Boehringer Ingelheim$149
  • Sanofi$130
  • Fresenius Kabi USA, LLC$125
  • Actelion Pharmaceuticals US, Inc.$78
  • plus $537 from 14 others

What the payments were for

  • Food & beverage$1,52399%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,535 in reported general payments places this provider in the 75th percentile of 442 critical care medicine providers in New York.

See all critical care medicine providers in New York

Medicare billing

Part B allowed, 2024
$180,427
Medicare patients
415
Services billed
1,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter87$61,602
Breo ElliptaFluticasone/Vilanterol41$17,828
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,149
Spiriva HandihalerTiotropium Bromide14$7,199
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,052
Albuterol Sulfate HfaAlbuterol Sulfate104$2,818
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,276
Azelastine Hcl13$293
Prednisone36$113
Montelukast Sodium12$79
Furosemide18$20

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$242$85,483141 claims
AstraZenecaBreztri Aerosphere$273$9,14915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 442 critical care medicine providers in New York.

Other critical care medicine in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →